Quick navigation menu :

  1. Go to the content
  2. Go to main section's menu
  3. Go to Search tool
  4. Go to Help menu
  5. Go to modules
  6. Go to the list of keyboard shortcuts

This site uses cookies to store information on your computer. Some cookies on this site are essential and the site won’t work as expected without them. To learn more about cookies and their benefits, please view our cookies policy. You could also decide what kind of cookie the website could use or not use on our cookies settings page.
By closing this message or navigating within the website, you consent to our use of cookies on this device in accordance with our cookie policy unless you have disabled them.

Help menu :

  1. Sanofi Worldwide |
     
  2. Our UK Websites |
     
  3. Global Business Websites |
     
  4. Contact us |
  5. Site map |
  6. Help
  1. RSS
  2. Font size

    Reduce font size Increase font size  
 
 

Research and Development

Content :

Partnerships

January 21, 2013

Our partnership strategy, particularly in biotechnologies and biotherapy, forges strategic collaborations with recognised experts around the world to achieve faster, better progress towards new therapeutic solutions.

 

Innovation begins with creative curiosity, an open mind and a spirit of collaboration: future successes in medicine, where team spirit has always been vital, will come from building on shared ideas.

At every level, Sanofi is committed to turning external scientific breakthroughs into successful innovative products.  As a global enterprise, we seek out public and private partnerships that will open doors to new solutions for better health and we are determined to remain at the cutting edge in the field of biotherapy, stem cells and regenerative medicine, as well as expanding our portfolio with services or technologies beyond our current key areas of research.  In 2011 we expanded our growth through 30 new acquisitions and partnerships and we now have products in areas our own internal programmes have not yet explored:

  • We have been working with Regeneron to develop and commercialise human therapeutic antibodies, and in August 2012 Sanofi and Regeneron will share promotion rights to Zaltrap which was approved by the FDA

  • Our acquisition of the French biopharmaceutical company Fovea gives Sanofi a unique technology platform and several discovery programmes dedicated to diseases of the back of the eye, including investigating Ecallantide for treating retinal vein occlusion induced macular edema

  • In vaccines, Sanofi Pasteur MSD recently partnered with the Dutch firm Crucell to develop a new generation of monoclonal antibodies to fight rabies

In the UK, we have invested in external R&D and clinical trials, and partner a strong and diverse range of universities and related institutions with established technology transfer groups.  These include partnering the Juvenile Diabetes Research Foundation in the area of autoimmunity and beta cell regeneration and collaborating with Oxford BioMedica to develop novel gene-based medicines.

With ongoing demands for vaccines, Sanofi Pasteur MSD has developed partnership opportunities to boost its development and production capabilities for both prophylactic and therapeutic human vaccines.  Key focus is on global solutions for multi drug-resistant infections in hospitals and nursing homes and solutions for neglected diseases in developing countries.

Module :

Corporate Information

Corporate Information

 

Sitewide_Sanofi_In_The_UK

Sanofi in the UK

Find out more about Sanofi UK's business units and locations, our investment in research and development, and our product pipeline

 

Sitewide_Sustainability

Sustainability

Sanofi is respected as a global leader in healthcare, partly because of the benefits of our medicines and vaccines, and also because of the ethical way we engage with patients, customers, colleagues, suppliers and healthcare authorities.